Enhanced oral bioavailability of an etoposide multiple nanoemulsion incorporating a deoxycholic acid derivative–lipid complex

References

• Al-Hilal TA, Chung SW, Alam F, et al. (2014). Functional transformations of bile acid transporters induced by high-affinity macromolecules. Sci Rep 4:4163.
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Pallet N, Rabant M, et al. (2006). Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine–sirolimus interaction. Kidney Int 70:1019–25.
   PubMed Web of Science ®Google Scholar
• Artursson P, Magnusson C. (1990). Epithelial transport of drugs in cell culture. II: effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. J Pharm Sci 79:595–600.
   PubMed Web of Science ®Google Scholar
• Beig A, Fine-Shamir N, Porat D, et al. (2017). Concomitant solubility–permeability increase: vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide. Eur J Pharm Biopharm 121:97–103.
   PubMed Web of Science ®Google Scholar
• Beig A, Miller JM, Lindley D, et al. (2015). Head-to-head comparison of different solubility-enabling formulations of etoposide and their consequent solubility–permeability interplay. J Pharm Sci 104:2941–7.
   PubMed Web of Science ®Google Scholar
• Bisogno G, Cowie F, Boddy A, et al. (1998). High-dose cyclosporin with etoposide-toxicity and pharmacokinetic interaction in children with solid tumours. Br J Cancer 77:2304–9.
   PubMed Web of Science ®Google Scholar
• Burd CG. (2011). Physiology and pathology of endosome-to-Golgi retrograde sorting. Traffic 12:948–55.
   PubMed Web of Science ®Google Scholar
• Chung JY, Ko JH, Lee YJ, et al. (2018). Surfactant-free solubilization and systemic delivery of anti-cancer drug using low molecular weight methylcellulose. J Control Release 276:42–9.
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley JF, Saivin S, et al. (2000). Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 50:576–9.
   PubMed Web of Science ®Google Scholar
• Dawson PA, Karpen SJ. (2015). Intestinal transport and metabolism of bile acids. J Lipid Res 56:1085–99.
   PubMed Web of Science ®Google Scholar
• Ghadi R, Dand N. (2017). BCS class IV drugs: highly notorious candidates for formulation development. J Control Release 248:71–95.
   PubMed Web of Science ®Google Scholar
• Hande K, Messenger M, Wagner J, et al. (1999). Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 5:2742–7.
   PubMed Web of Science ®Google Scholar
• He B, Lin P, Jia Z, et al. (2013). The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. Biomaterials 34:6082–98.
   PubMed Web of Science ®Google Scholar
• Joel SP, Clark PI, Heap L, et al. (1995). Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 37:125–33.
   PubMed Web of Science ®Google Scholar
• Kanda T, Foucand L, Nakamura Y, et al. (1998). Regulation of expression of human intestinal bile acid-binding protein in Caco-2 cells. Biochem J 330:261–5.
   PubMed Web of Science ®Google Scholar
• Khalid N, Sarfraz M, Arafat M, et al. (2018). Nano-sized droplets of self-emulsifying system for enhancing oral bioavailability of chemotherapeutic agent VP-16 in rats: a nano lipid carrier for BCS class IV drugs. J Pharm Pharm Sci 21:398–408.
   PubMed Web of Science ®Google Scholar
• Kim K, Yoon I, Chun I, et al. (2011). Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats. Drug Deliv 18:79–83.
   PubMed Web of Science ®Google Scholar
• Klausner RD, Donaldson JG, Lippincott-Schwartz J. (1992). Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 116:1071–80.
   PubMed Web of Science ®Google Scholar
• Li X, Choi JS. (2009). Effects of quercetin on the pharmacokinetics of etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 29:1411–5.
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59–98.
   PubMed Web of Science ®Google Scholar
• Mo R, Xiao Y, Sun M, et al. (2011). Enhancing effect of N-octyl-O-sulfate chitosan on etoposide absorption. Int J Pharm 409:38–45.
   PubMed Web of Science ®Google Scholar
• Pangeni R, Choi SW, Jeon O-C, et al. (2016). Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation. Int J Nanomedicine 11:6379–99.
   PubMed Web of Science ®Google Scholar
• Park J, Choi JU, Kim K, et al. (2017). Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex. Biomaterials 147:145–54.
   PubMed Web of Science ®Google Scholar
• Piao YJ, Li X, Choi JS. (2008). Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats. Eur J Drug Metabol Pharmacokinet 33:159–64.
   PubMed Web of Science ®Google Scholar
• Qu X, Zou Y, He C, et al. (2018). Improved intestinal absorption of paclitaxel by mixed micelles self-assembled from vitamin E succinate-based amphiphilic polymers and their transcellular transport mechanism and intracellular trafficking routes. Drug Deliv 25:210–25.
   PubMed Web of Science ®Google Scholar
• Sha X, Yan G, Wu Y, et al. (2005). Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci 24:477–86.
   PubMed Web of Science ®Google Scholar
• Slevin ML, Joel SP. (1993). Prolonged oral etoposide in small cell lung cancer. Ann Oncol 4:529–32.
   PubMed Web of Science ®Google Scholar
• Solano AG, de F, Pereira A, et al. (2013). Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants. AAPS PharmSciTech 14:890–900.
   PubMed Web of Science ®Google Scholar
• Stuurman FE, Nuijen B, Beijnen JH, et al. (2013). Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet 52:399–414.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Corona G, Sorio R, et al. (2001). Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 52:511–9.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Corona G, Basso B, Boiocchi M. (2004). Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 43:441–66.
   PubMed Web of Science ®Google Scholar
• van de Wiel SMW, de Waart DR, Oude Elferink RPJ, et al. (2018). Intestinal farnesoid X receptor activation by pharmacologic inhibition of the organic solute transporter α-β. Cell Mol Gastroenterol Hepatol 5:223–37.
   PubMed Web of Science ®Google Scholar
• Varsha K, Sharma A, Kaur A, et al. (2017). Chapter 28 – natural plant-derived anticancer drugs nanotherapeutics: a review on preclinical to clinical success. In: Ficai A, Grumezescu AM, eds. Nanostructures for cancer therapy. Netherlands: Elsevier, 775–809.
   Google Scholar
• Wang J, Zhang Y, Guan T, et al. (2009). Determination of teniposide in rat plasma by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry after intravenous administration. Biomed Chromatogr 23:999–1006.
   PubMed Web of Science ®Google Scholar
• Wu C, Yi X, Xu R, et al. (2020). Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants. Drug Deliv 27:974–82.
   PubMed Web of Science ®Google Scholar
• Ye J, Wu H, Huang C, et al. (2019). Comparisons of in vitro Fick's first law, lipolysis, and in vivo rat models for oral absorption on BCS II drugs in SNEDDS. Int J Nanomedicine 14:5623–36.
   PubMed Web of Science ®Google Scholar
• Zhang F, Koh GY, Hollingsworth J, et al. (2012). Reformulation of etoposide with solubility-enhancing rubusoside. Int J Pharm 434:453–9.
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen J, Zhang Y, et al. (2011). Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 43:174–9.
   PubMed Web of Science ®Google Scholar